HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

HLS.TO Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

HLS Therapeutics Inc.TSX: HLS.TO

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -$78.69K, compared with -$2.27M a year earlier. Trailing-twelve-month other income / expenses was -$6.61M.

Context

  • Other income / expenses amounted to 15.8% of revenue in FY2025, up 1.9 pp from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$78.69K or moves back toward the trailing-twelve-month quarterly average of -$1.65M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$78.69K+96.5% QoQ
Last fiscal yearDec 2025
-$8.92M-13.0% YoY
LTMMar 2026
-$6.61M+11.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.5%——
1 year-13.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(8.92M) USD
Year-over-year change
-13.0%

Other Income / Expenses vs competitors

How HLS.TO compares with its peers on the latest reported figures

  • HLS.TO's LTM Mar 2026 other income / expenses of -$6.61M is the 3rd highest of the 7 companies compared; the peer median is -$107.54M.
  • Its year-over-year change of +11.8% is the 3rd highest of 7, against a peer median of -28.9%.
  • Other income / expenses amounts to 11.9% of revenue for HLS.TO, versus a peer median of 6.5%.
HLS.TO Competitors Peer median
Other Income / Expenses for HLS.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-$2.18K +95.7%—0.0%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026-$3.53M -58.3%—4.1%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026-$6.61M +11.8%—11.9%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$13.02M +0.4%—25.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026-$202.06M +29.6%—6.5%
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$359.21M -1411.2%——
BHCBausch Health Companies Inc.LTM Jun 2026-$3.49B -159.9%—32.2%
Peer median (excluding HLS.TO) -$107.54M-28.9%—6.5%

Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.01M61.47M63.07M56.62M56.47M
Cost of Revenue3.97M4.98M7.62M9M32.46M
Gross Profit56.04M56.49M55.45M47.62M24.01M
Gross Margin93.4%91.9%87.9%84.1%42.5%
Research & Development00000
Selling, General & Admin32.06M35.58M28.29M26.93M22M
Operating Expenses62.32M69.98M55.45M55.31M28.19M
Depreciation & Amortization30.26M34.4M31.94M22.72M22.2M
EBITDA25.41M18M12.88M17.22M18.02M
EBITDA Margin42.3%29.3%20.4%30.4%31.9%
Operating Income(6.24M)(13.44M)(10.35M)(7.69M)(4.18M)
Operating Margin-10.4%-21.9%-16.4%-13.6%-7.4%
Interest Income44K57K350K319K108.87K
Interest Expense6.96M7.32M8.75M10.08M7.22M
Other Income / Expenses(5.52M)(10.23M)(17.45M)(7.9M)(8.92M)
Income Before Tax(11.81M)(23.72M)(27.8M)(15.58M)(13.1M)
Pre-Tax Margin-19.7%-38.6%-44.1%-27.5%-23.2%
Income Tax Expense1.31M(124K)(272K)4.07M(452.79K)
Net Income(13.12M)(23.6M)(27.53M)(19.66M)(12.65M)
Net Margin-21.9%-38.4%-43.6%-34.7%-22.4%
EPS (Basic)(0.41)(0.73)(0.85)(0.62)(0.40)
EPS (Diluted)(0.41)(0.73)(0.85)(0.62)(0.40)
Weighted Avg Shares32.18M32.33M32.26M31.84M31.53M
Weighted Avg Shares (Diluted)32.18M32.43M32.26M31.84M31.53M

HLS Therapeutics Inc.

TSX:HLS.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.